A recent study showed that inhibiting MAP4K2 with BAY61-3606 can sensitize KRAS wild-type colorectal cancer cells to AZ628, a RAF kinase inhibitor, suggesting a potential therapeutic strategy for treating colorectal cancer [291]. The gene discussed is KRAS; the disease is colorectal cancer.